Table 3.

Adverse events of neoadjuvant HER2-targeted treatment

Adverse Events (AEs)	Total		TCbHP(n = 130)		AC/EC-THP(n = 46)		others(n = 3)
	All grades	Grade3 ~ 4	All grades	Grade3 ~ 4	All grades	Grade3 ~ 4	All grades	Grade3 ~ 4
Leukopenia	42(23.5%)	9(5.0%)	35(26.9%)	4(3.1%)	6(13.0%)	1(2.2%)	1(33.3%)	1(33.3%)
Neutropenia	37(20.7%)	11(6.1%)	31(23.8%)	9(6.9%)	5(10.9%)	1(2.2%)	1(33.3%)	1(33.3%)
Thrombocytopenia	26(14.5%)	6(3.4%)	25(19.2%)	5(3.8%)	0	0	1(33.3%)	0
Anemia	111(62.0%)	4(2.2%)	90(69.3%)	4(3.1%)	19(41.3%)	0	2(66.7%)	0
LEVF decrease	0	0	0	0	0	0	0	0
Transaminase increase	21(11.7%)	4(2.2%)	17(13.1%)	1(0.8%)	3(6.5%)	2(4.3%)	1(33.3%)	0
Creatinine increase	4(2.2%)	1(0.6%)	3(2.3%)	0	1(2.2%)	1(2.2%)	0	0